About this episode

The episode discusses a clinical trial conducted by Japanese startup Heartseed Inc. involving the injection of heart muscle cells derived from iPS cells into patients with severe heart failure.

Japanese startup Heartseed Inc. has said it conducted a clinical trial to inject via catheter small masses of heart muscle cells produced from induced pluripotent stem, or iPS, cells into patients with severe heart failure.

Topics covered

• healthcare
• clinical trials
• iPS cells
• heart failure
• biotechnology

Mentioned in this episode

Organizations: Heartseed Inc.

Places: Japan

More episodes of JIJI English News-時事通信英語ニュース-

• Japan Eyes Responsibility of Social Media Users during Elections · June 13, 2026 · 0 min
• China Rattling Sabers in Crackdowns on Vessels off Eastern Taiwan · June 13, 2026 · 0 min
• Japan PM Takaichi Leaves for Europe for G7 Summit · June 13, 2026 · 0 min
• Japan Releases Tool to Visualize Local Govt Finances · June 13, 2026 · 0 min
• Japan's Takaichi Vows Cooperation for Hormuz Safety: FT · June 13, 2026 · 0 min
• Japan Imperial Couple Departs for Trip to Netherlands, Belgium · June 13, 2026 · 0 min

Explore listener stats, chart rankings, contacts and more on the JIJI English News-時事通信英語ニュース- podcast page.